Daiichi Sankyo’s Vanflyta (quizartinib) has been recommended by the National Institute for Health and Care Excellence (NICE) ...

Roche’s injectable PD-L1 inhibitor Tecentriq Hybreza (atezolizumab and hyaluronidase-tqjs) has been approved by the US Food ...

Merck & Co – known as MSD outside the US and Canada – has shared positive overall survival (OS) results from a late-stage ...

Merck & Co – known as MSD outside the US and Canada – and Daiichi Sankyo have announced that a late-stage trial of patritumab deruxtecan in non-small cell lung cancer (NSCLC) met its primary endpoint ...

Eli Lilly has announced that the US Food and Drug Administration (FDA) has approved its targeted IL-13 inhibitor Ebglyss (lebrikizumab-lbkz) to treat moderate-to-severe atopic dermatitis (AD). The ...

Post-treatment follow-up of patients is not new. Traditional follow-up studies may last two to five years, while long-term follow-up (LTFU) studies can last from 15 years to a lifetime. Cell and gene ...

Johnson & Johnson’s (J&J) Rybrevant (amivantamab-vmjw) combination has demonstrated a positive overall survival trend in adults with lung cancer, according to new late-stage results shared by the ...

AstraZeneca’s (AZ) Fasenra (benralizumab) has been approved by the US Food and Drug Administration (FDA) to treat adults with eosinophilic granulomatosis with polyangiitis (EGPA), a rare ...

It was very disconcerting. For a fraction of a second, as I sat in a plush, modern boardroom, there across the table from me sat a magnificent giraffe, slowly ruminating as its small horns and large ...

Merck & Co – known as MSD outside the US and Canada – has received approval from the US Food and Drug Administration (FDA) for the use of Keytruda (pembrolizumab) in malignant pleural mesothelioma.